NL-OMON39544
Completed
Phase 3
A double blind randomized placebo controlled study on the efficacy of intralymphatic immunotherapy in the treatment of grasspollen induced allergic rhinitis. - ILIT
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Allergic rhino-conjunctivitis
- Sponsor
- HagaZiekenhuis
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Sensibilisation to grass pollen
- •age between 18 and 50 years old
- •Informed consent
Exclusion Criteria
- •No informed consent
- •instable or steroidtherapy dependent atopic astma
- •rhinosinusitis
- •nasal polyps
- •vasomotore rhinitis
- •immunosupressive medication
- •immuondeficiancy (IgG\-IgA deficiaccy, HIV\-AIDS)
- •pregnany or nursing
- •participation in other medical study
- •history of desensibilisation therapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Withdrawn
Phase 2
A randomized double blind placebo controlled study on the effects of fenretinide Lym-X-Sorb on insulin sensitivity in obese insulin resistant subjectsobesitasInsulin resistanceimpaired glucose tolerance1001842410019654NL-OMON37344Academisch Medisch Centrum20
Active, not recruiting
Phase 1
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients”EUCTR2018-004705-26-ESSanofi Aventis Groupe188
Active, not recruiting
Phase 1
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patientsEUCTR2018-004705-26-ITSANOFI-AVENTIS GROUPE188
Active, not recruiting
Phase 1
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients”Atopic dermatitisMedDRA version: 20.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-004705-26-FRSanofi Aventis Groupe268
Active, not recruiting
Phase 1
SAR231893-LPS15497- Dupilumab effect on Sleep in AD patients”EUCTR2018-004705-26-DESanofi Aventis Groupe268